Brainsway Ltd

Brainsway Ltd

9.39
USD
-0.72
(-7.12%)
0.25EPS
48.89P/E
530.85MMarket Cap
Brainsway Ltd
NASDAQ:BWAY
(Nasdaq Stock Market)

Recent

price

9.39

P/E

ratio

48.89

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
0.09
0.24
0.47
0.8
0.76
0.99
1.13
0.98
0.96
0.82
0.99
1.26
1.37
1.74
Revenue per Share
-0.55
-0.46
-0.28
-0.17
-0.48
-0.39
-0.5
-0.24
-0.21
-0.4
-0.13
0.09
0.2
0.27
Basic EPS, GAAP
-0.5
-0.37
-0.47
-0.19
-0.3
-0.35
-0.52
-0.17
-0.04
-0.29
0.04
0.2
0.43
0.3
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
1.08
0.89
0.7
0.77
0.42
1.09
0.88
1.74
1.37
1.25
1.66
1.87
2.04
Book Value per Share
- -
1.08
0.89
0.7
0.76
0.42
1.09
0.88
1.74
1.37
1.25
1.66
1.87
2.04
Tangible Book Value per Share
13
14
14
14
15
17
20
22
31
33
32
32
38
38
Basic Weighted Avg Shares
1
3
7
12
11
16
23
22
30
27
32
41
52
65
Sales/Revenue/Turnover
-358.87
-215.3
-66.25
-17.95
-59.32
-31.19
-36.69
-21.89
-16.86
-46.67
-15.6
3.39
8.28
13.63
Operating Margin (%)
- -
- -
1
1
1
1
2
2
2
2
1
2
2
2
Depreciation Expense
-7
-7
-4
-2
-7
-6
-10
-5
-6
-13
-4
3
8
10
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
15.55
1
- -
Effective Tax Rate (%)
-598.99
-193.64
-60.1
-20.8
-63.29
-39.51
-44.71
-24.41
-21.79
-49.12
-13.2
7.12
14.62
15.54
Profit Margin (%)
- -
14
10
9
12
5
22
17
56
50
46
64
63
53
Working Capital
- -
- -
- -
- -
3
2
- -
- -
- -
- -
- -
5
6
6
LT Debt
- -
16
13
10
13
7
24
20
57
45
42
62
73
82
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
2.16
5.82
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
7.64
13.27
- -
Return on Capital (%)
- -
- -
-28.71
-20.68
-61.32
-65.87
-66.26
-24.56
-16.79
-25.99
-9.65
5.62
11.26
13.34
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
6
6
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
40
40
40
Market Capitalization
532
622
531

Working Capital

USD

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
79
81
81
Cash, Cash Equivalents & STI
60
63
64
Accounts Receivable, Net
8
7
7
Inventories
7
7
8
Total Current Liabilities
24
23
28
Payables & Accruals
11
9
8
ST Debt
1
1
1
Deferred Revenue
12
12
19

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
41.77%
46.02%
17.51%
Free Cash Flow
104.85%
199.81%
150.2%
Net Income, GAAP
20.61%
9.95%
161.31%
Sales/Revenue/Turnover
24.91%
19.89%
27.33%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
9
10
11
11
41
2025
12
13
14
15
52
2026
16
17
18
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.02
0.02
0.04
0.09
2025
0.03
0.05
0.04
0.08
0.2
2026
0.06
0.07
0.06
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
BrainsWay Ltd. (NASDAQ & TASE: BWAY.TA), founded in 2003 and headquartered in Jerusalem, Israel, with principal U.S. operations in Burlington, Massachusetts, develops and markets noninvasive neurostimulation treatments utilizing its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology for mental health disorders. The company offers FDA-cleared Deep TMS systems for major depressive disorder including anxious depression and late-life depression in patients aged 15 to 86, obsessive-compulsive disorder as the first de novo noninvasive device, and short-term smoking addiction cessation as the inaugural TMS clearance in the addiction category; it targets treatment-resistant patients and operates through over 800 providers in the United States, East Asia, and internationally. BrainsWay pursues ongoing clinical trials in additional psychiatric, neurological, and addiction indications while maintaining dual listings on NASDAQ and the Tel Aviv Stock Exchange. In August 2025, the company acquired a minority stake in Axis Integrated Mental Health for up to $3.3 million through strategic equity financing to support provider growth and Deep TMS adoption, following a prior $5 million convertible loan to Neurolief Ltd. for potential acquisition of complementary neuromodulation technology; these moves align with a late-2024 initiative for minority investments in U.S. mental health providers amid 26% year-over-year Q2 2025 revenue growth to $12.6 million.

Company News

  • BrainsWay: 3 Key Takeaways for Long-Term Investors

  • What Brainsway (BWAY) Said on Its Q3 Earnings Call

  • BrainsWay Ltd. (BWAY) Q3 2026 Earnings Call Transcript

  • BrainsWay to Report Third Quarter 2026 Financial Results on November 10, 2026

  • BrainsWay Expands U.S. Insurance Coverage for Deep TMS™ Treatment of OCD to Over 118 Million Lives

  • BrainsWay Announces Strategic Collaboration with Inland Psychiatry Medical Group

  • BrainsWay Reports Rise in Favorable Accelerated Deep TMS™ Coverage to Over 70 Million Covered Lives

  • HWG Holdings LP Buys New Stake in Brainsway Ltd. Sponsored ADR $BWAY

  • Head to Head Survey: CapsoVision (NASDAQ:CV) vs. Brainsway (NASDAQ:BWAY)

  • Brainsway (NASDAQ:BWAY) Shares Gap Down – What’s Next?

  • BrainsWay Reports Promising Pilot Study Results in Patients with Depression and Comorbid Early-Stage Alzheimer's Disease Treated with Deep TMS™

  • Analyzing Brainsway (NASDAQ:BWAY) and Green Thumb Industries (OTCMKTS:GTBIF)

  • Wall Street Analysts See a 30.07% Upside in Brainsway (BWAY): Can the Stock Really Move This High?

  • Brainsway (BWAY) Upgraded to Buy: Here's Why

  • Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) Receives $16.95 Average Target Price from Brokerages

  • Brainsway Q2 Earnings Call Highlights

  • BrainsWay Ltd. (BWAY) Q2 2026 Earnings Call Transcript

  • BrainsWay Reports Second Quarter 2026 Financial Results and Operational Highlights

  • BrainsWay: Building A Capital-Light Interventional Psychiatry Ecosystem

  • Brainsway (NASDAQ:BWAY) Sets New 52-Week High – Here’s What Happened